|
Post by yash on May 4, 2017 7:06:43 GMT -5
MannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes VALENCIA, Calif. and NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) TASE:MNKD) and One Drop today announced that they have signed a memorandum of understanding to enter into a collaborative agreement that would extend One Drop’s subscription service and digital health platform – which currently provides unlimited blood glucose testing supplies and 24/7 live in-app support from diabetes experts – by adding Afrezza as a rapid-acting insulin offering. finance.yahoo.com/news/mannkind-one-drop-collaborate-delivering-120000410.html
|
|
|
Post by peppy on May 4, 2017 7:25:19 GMT -5
|
|
|
Post by mnholdem on May 4, 2017 7:28:01 GMT -5
The planned collaboration will include three consumer-focused areas: 1. Access, Cost Savings and Convenience initiatives, intended to simplify the complexity of starting and staying on mealtime insulin. 2. Customized Coaching and Engagement designed to help people on Afrezza achieve the American Diabetes Association (ADA) recommendation of an A1C goal of less than 7%. 3. Design innovation around packaging and exploration of a reusable Afrezza Inhaler with integrated Bluetooth technology.
---
"Against a backdrop of soaring insulin costs, this proposed collaboration is an essential step in the right direction," said Jeff Dachis, CEO and Founder of One Step. "One Drop began with the goal of bringing affordable, accessible diabetes care to everyone living with diabetes worldwide. Through this partnership with MannKind, we will continue to work tirelessly to empower everyone with diabetes to achieve better health outcomes through the use of modern delivery methods that reduce the burden of diabetes management and increase engagement in self-care." "The complexity and conflicting incentives of the United States healthcare system are not aligned to help people with diabetes on insulin achieve optimal outcomes, as we see that almost seven out of ten people on mealtime insulin are not at the ADA goal of <7% A1C," said Michael Castagna, Chief Commercial Officer of MannKind Corporation. "Even though injectable insulins have been available for decades, 20% of users regularly skip injections. We intend to empower people with diabetes to take charge of their health by trying something different."
"We believe that diabetes care as a fully integrated digital service is the only way that we are going to bend the cost curve for payers and providers, while at the same time delivering evidence-based health outcomes that can scale," continued Dachis. "Working with an innovator like MannKind, with a clinically effective, non-invasive inhaled mealtime insulin product, offers up an exciting opportunity to further our mission of relentlessly improving the lives of everyone with diabetes and a smartphone."
|
|
|
Post by mnholdem on May 4, 2017 7:37:09 GMT -5
Premarket MNKD is already +12.08% minutes after the press release. This should be a VERY good day.
|
|
|
Post by kbrion77 on May 4, 2017 7:37:13 GMT -5
It's the right direction and could have long term benefit (funny how Dexcom or Medtronic had no interest) but does not solve the current cash constraint. Need to keep coming through with announcements.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 4, 2017 7:38:57 GMT -5
A step in the right direction.
One thing Matt knows how to do is stretch the runway.
Waiting for the next break with funding and partnership.
|
|
|
Post by peppy on May 4, 2017 7:42:37 GMT -5
|
|
|
Post by factspls88 on May 4, 2017 7:44:13 GMT -5
This is fantastic - made my day! Users will have access to coaching - just what Afrezza users need. I hope Mannkind takes full advantage of this coaching to directly engage the patient in the titration of Afrezza. I wonder if One Drop will be featured in "Reversed" as well.
|
|
|
Post by boytroy88 on May 4, 2017 7:49:04 GMT -5
Dang...I was telling myself that I should average down the last two days but just couldn't...LOL...oh well. Hope this is the turnaround we all were looking for!
|
|
|
Post by myocat on May 4, 2017 7:59:57 GMT -5
Dang...I was telling myself that I should average down the last two days but just couldn't...LOL...oh well. Hope this is the turnaround we all were looking for! Wait for a blizzard of negative coverages coming out soon.
|
|
|
Post by nadathing on May 4, 2017 8:07:05 GMT -5
Dang...I was telling myself that I should average down the last two days but just couldn't...LOL...oh well. Hope this is the turnaround we all were looking for! Wait for a blizzard of negative coverages coming out soon. The big question is how MNKD raises cash to stay in business. While this is good news, that still has to be answered.
|
|
|
Post by boytroy88 on May 4, 2017 8:15:35 GMT -5
Dang...I was telling myself that I should average down the last two days but just couldn't...LOL...oh well. Hope this is the turnaround we all were looking for! Wait for a blizzard of negative coverages coming out soon. Yeah...one of the "momentum" stock boards I frequent have one of its prominent members recommending shorting MNKD on any spikes. So unless we have definitive funding coming this spike in SP will not last. OT - Hmmmm...funny haven't seen Sports, Peppy, and the other "morning posters" post this morning....
|
|
|
Post by sportsrancho on May 4, 2017 8:23:44 GMT -5
|
|
|
Post by silentknight on May 4, 2017 8:28:25 GMT -5
Dang...I was telling myself that I should average down the last two days but just couldn't...LOL...oh well. Hope this is the turnaround we all were looking for! You'll still be able to average down pretty well. It's only at .80 premarket. If you're like me, 7 cents wouldn't make that much of a difference if you're trying to average down. For me, I'm still in a wait and see mode for scripts to pick up. Good announcement but we'll see what impact it has.
|
|
|
Post by derek2 on May 4, 2017 8:29:29 GMT -5
Wait for a blizzard of negative coverages coming out soon. Yeah...one of the "momentum" stock boards I frequent have one of its prominent members recommending shorting MNKD on any spikes. So unless we have definitive funding coming this spike in SP will not last. OT - Hmmmm...funny haven't seen Sport, Peppy, and the other "morning posters" post this morning.... If you want the "wet blanket" version: (If by wet blanket, you mean positive, but not wetting my pants positive) Nice looking app for tracking and coaching. Very masculine looking meter and lancet. All-you-can-eat strips. The collaboration means that Onedrop will make Afrezza one of the treatments trackable through their app, and they'll look at developing a bluetooth enabled inhaler. I don't think it implies that Afrezza - a prescription-omnly med - gets added to the subscription service. I think just to the app. Positive news but really not revolutionary. Absent any other news, or a financial strategy, an opportunity to sell at a better price maybe or buy puts at a better price. This, then, may serve as an example of 1. reading news as it is rather than as you hope it is 2. determining how markets will react both in the short and longer term 3. acting on it and possibly getting an advantage over those who act less rationally I suspect there will be a short-term pop followed by buying exhaustion after retails run out of cash or interest. 80% of this app is already applicable to any diabetic, regardless of treatment used. I take it as a positive, but not a huge deal. Of course, maybe it could spark a run, esp if followed up with other positive news. If MNKD wanted to make an impact, Afrezza would already be integrated into the app and the Bluehale-based new inhaler would already be submitted for approval. Instead they're still talking about what will happen in the future. But hey - narrative. Another carrot.
|
|